A Study YL201 in Patients With Selected Advanced Solid Tumors
A Multicenter, Open-Label, Phase 1/2 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Selected Advanced Solid Tumors
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
A PHASE1/PHASE2 clinical study on Advanced Solid Tumor, this trial is ongoing. The trial is conducted by MediLink Therapeutics (Suzhou) Co., Ltd. and has accumulated 8 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2025 — Mar 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Mar 2025 — Dec 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
▶ Show 3 earlier versions
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2023 — Dec 2023 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Sep 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MediLink Therapeutics (Suzhou) Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Changsha, China , Changzhou, China , Chengde, China , Chengdu, China , Chongqing, China , Datong, China , Dongguan, China , Foshan, China and 29 more locations